For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

This important study shows that the activity of hypothalamic hypocretin/orexin neurons (HONs) correlates with body movement over multiple behaviors. Sophisticated techniques and analyses showcase this ...

Neurons that secrete the neuropeptide orexin help mice decide between exercise and snacking. I n neurobiologist Daria ...

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...